Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 5/20 | 0.84 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | POLB | P06746 | 1/20 | 0.84 |
| ▸ | GAA | P10253 | 1/20 | 0.84 |
| ▸ | HPGD | P15428 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 6/20 | 0.57 |
| ▸ | ATIC | P31939 | 3/20 | 0.56 |
| ▸ | GART | P22102 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13011046 | 1.00 | TYMS (0.84) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL470145 | 0.93 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL10173120 | 0.93 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL12523472 | 0.93 | AKR1B1 (0.81) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| Folic Acid SCHEMBL23581079 | 0.93 | TYMS (0.92) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL22758092 | 0.92 | TYMS (0.83) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL22758155 | 0.92 | TYMS (0.83) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL21664561 | 0.92 | TYMS (0.85) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL18533392 | 0.92 | TYMS (0.80) | TYMSAKR1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL19738969 | 0.92 | TYMS (0.80) | TYMSAKR1B1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20210299285-A1 | COMPOUNDS USEFUL FOR IN VIVO IMAGING OF PROTEIN OXIDATION AND/OR CANCER TREATMENT | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2021-09-30 | — | — | US | disclosed |
| US-20200384010-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | SHIONOGI & CO., LTD. (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3603648-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | Shionogi & Co., Ltd (JP) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020018613-A1 | COMPOUNDS USEFUL FOR IN VIVO IMAGING OF PROTEIN OXIDATION AND/OR CANCER TREATMENT | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2018057649-A1 | TAGGED POLY(ESTER AMIDE URETHANE)S, NANOPARTICLES FORMED FROM SAME, AND USES THEREOF | CORNELL UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20160362434-A1 | METHODS AND COMPOUNDS FOR ENHANCING CONTRAST IN MAGNETIC RESONANCE IMAGING (MRI) | BROCK UNIVERSITY (CA) | 2016-12-15 | — | — | US | disclosed |
| US-20140271468-A1 | ASTHMA IMAGING | PURDUE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8765096-B2 | Methods and compositions for treating and diagnosing kidney disease | ENDOCYTE, INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130266964-A1 | METHOD OF DETECTING ENDOTHELIAL PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130266964-A1 | METHOD OF DETECTING ENDOTHELIAL PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2013-10-10 | — | — | US | disclosed |
| US-20090324726-A1 | Non-Viral Gene Therapy Using Chitosan-Containing Nanoparticles | FERNANDES JULIO C | 2009-12-31 | — | — | US | disclosed |
| US-20090324726-A1 | Non-Viral Gene Therapy Using Chitosan-Containing Nanoparticles | FERNANDES JULIO C | 2009-12-31 | — | — | US | disclosed |
| US-20090214636-A1 | Imaging and Therapeutic Method Using Monocytes | LOW PHILIP S | 2009-08-27 | — | — | US | disclosed |
| US-20090214636-A1 | Imaging and Therapeutic Method Using Monocytes | LOW PHILIP S | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299285-A1 | COMPOUNDS USEFUL FOR IN VIVO IMAGING OF PROTEIN OXIDATION AND/OR CANCER TREATMENT | QSOX1, GPX4, SDHA | TYMS 773/4885AKR1B1 582/4885KDM4E 3379/4885 |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | TYMS 691/4885AKR1B1 2035/4885KDM4E 3088/4885 |
| US-20200384010-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | FABP1, POLRMT, SREBF1 | TYMS 691/4885AKR1B1 2035/4885KDM4E 3088/4885 |
| US-20090324726-A1 | Non-Viral Gene Therapy Using Chitosan-Containing Nanoparticles | FOLR1, FOLR2, SLC19A1 | TYMS 23/4885AKR1B1 674/4885KDM4E 4235/4885 |
| US-20140271468-A1 | ASTHMA IMAGING | CYSLTR1, FCER2, MRGPRX2 | TYMS 3284/4885AKR1B1 818/4885KDM4E 3820/4885 |
| US-20090214636-A1 | Imaging and Therapeutic Method Using Monocytes | CD14, MYADM, CD68 | TYMS 3982/4885AKR1B1 1324/4885KDM4E 4421/4885 |
| US-20160362434-A1 | METHODS AND COMPOUNDS FOR ENHANCING CONTRAST IN MAGNETIC RESONANCE IMAGING (MRI) | PPIP5K2, FABP7, MPI | TYMS 2801/4885AKR1B1 467/4885KDM4E 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.